Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Molinuevo, José L ^a   Frölich, Lutz ^b   Grossberg, George T ^c   Galvin, James E ^d   Cummings, Jeffrey L ^e,f   Krahnke, Tillmann ^g   Strohmaier, Christine ^g  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING SCALE; ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DETERIORATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; FEMALE; FUNCTIONAL STATUS; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 84928170139     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-014-0088-8     Document Type: Article

References (18)

1. Small G, Bullock R. Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement. 2011;7:177-84.
2. Burns A, Yeates A, Akintade L, Del Valle M, Zhang RY, Schwam EM, et al. Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies. Drugs Aging. 2008;25:707-14.
3. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-64.
4. Rockwood K, Fay S, Gorman M, Carver D, Graham JE. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol. 2007;7:26.
5. Green C. Modelling disease progression in Alzheimer's disease: A review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics. 2007;25:735-50.
6. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11:33-9.
7. Gauthier S, Bodick N, Erzigkeit E, Feldman H, Geldmacher DS, Huff J, et al. Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997;11(Suppl. 3):6-7.
8. Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry. 2001;16:653-66.
9. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-97.
10. Sadowsky CH, Grossberg GT, Somogyi M, Meng X. Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: A retrospective analysis. Prim Care Companion CNS Disord. 2011;13:pii = PCC.10m01101. doi:10.4088/PCC.10m01101.
11. Farlow MR, Doraiswamy PM, Meng X, Cooke K, Somogyi M. The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease. Dement Geriatr Cogn Dis Extra. 2011;1:150-62.
12. Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33:341-53.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-44.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
15. Razani J, Kakos B, Orieta-Barbalace C, Wong JT, Casas R, Lu P, et al. Predicting caregiver burden from daily functional abilities of patients with mild dementia. J Am Geriatr Soc. 2007;55:1415-20.
16. Wattmo C, Wallin AK, Londos E, Minthon L. Risk factors for nursing home placement in Alzheimer's disease: A longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist. 2011;51:17-27.
17. Wattmo C, Wallin AK, Londos E, Minthon L. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord. 2011;25:63-72.
18. Hatoum HT, Thomas SK, Lin SJ, Lane R, Bullock R. Predicting time to nursing home placement based on activities of daily living scores - A modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil. J Med Econ. 2009;12:98-103.